Market revenue in 2023 | USD 465.4 million |
Market revenue in 2030 | USD 904.6 million |
Growth rate | 10% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer’s disease dementia |
Fastest growing segment | Lewy Body Dementia |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia, Other Indications |
Key market players worldwide | Eisai Co Ltd, Eli Lilly and Co, Novartis AG ADR, Daiichi Sankyo Co Ltd, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Cipla Ltd DR, Sun Pharmaceutical Industries, Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dementia treatment market will help companies and investors design strategic landscapes.
Alzheimer’s disease dementia was the largest segment with a revenue share of 60.14% in 2023. Horizon Databook has segmented the India dementia treatment market based on alzheimer’s disease dementia, vascular dementia, lewy body dementia, frontotemporal dementia (ftd), parkinson disease dementia, other indications covering the revenue growth of each sub-segment from 2018 to 2030.
The dementia treatment market in India is anticipated to grow at the fastest rate over the forecast period. Market growth in the country is supported by large target population, high unmet clinical needs, developing healthcare infrastructure, and a rising geriatric population.
Ongoing research in India encompasses synaptic plasticity therapies, novel molecule synthesis, and digital media innovations to enhance dementia care and explore stem cell treatments.
In October 2024, according to the Government of India, scientists from the Agharkar Research Institute, Pune, designed novel molecules for Alzheimer’s treatment, developing non-toxic molecules and used them to create selective cholinesterase inhibitors for potential application in India.
Horizon Databook provides a detailed overview of country-level data and insights on the India dementia treatment market, including forecasts for subscribers. This country databook contains high-level insights into India dementia treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account